Therefore, the higher apelin levels in patients with MMD may explain their greater capacity for arteriogenesis and angiogenesis and their better clinical prognoses and outcomes compared with those for patients with ICAD5, as well as provide a better understanding of the pathology and aetiology of MMD. This evidence concerns the gene APLN and multiminicore myopathy.